Role of CaMKII and PKA in early afterdepolarization of

human ventricular myocardium cell: A Computational

model study by Dai, Ling et al.
Research Article
Role of CaMKII and PKA in Early Afterdepolarization of Human
Ventricular Myocardium Cell: A Computational Model Study
Ling Dai,1 Yunliang Zang,1 Dingchang Zheng,2 Ling Xia,1 and Yinglan Gong1
1Department of Biomedical Engineering, Zhejiang University, Hangzhou, China
2Health and Wellbeing Academy, Faculty of Medical Science, Anglia Ruskin University, Chelmsford CM1 1SQ, UK
Correspondence should be addressed to Ling Xia; xialing@zju.edu.cn and Yinglan Gong; yinglangong@zju.edu.cn
Received 11 June 2016; Accepted 31 October 2016
Academic Editor: Xiaopeng Zhao
Copyright © 2016 Ling Dai et al.This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Early afterdepolarization (EAD) plays an important role in arrhythmogenesis. Many experimental studies have reported that
Ca2+/calmodulin-dependent protein kinase II (CaMKII) and 𝛽-adrenergic signaling pathway are two important regulators. In
this study, we developed a modified computational model of human ventricular myocyte to investigate the combined role of
CaMKII and 𝛽-adrenergic signaling pathway on the occurrence of EADs. Our simulation results showed that (1) CaMKII
overexpression facilitates EADs through the prolongation of late sodium current’s (𝐼NaL) deactivation progress; (2) the combined
effect of CaMKII overexpression and activation of 𝛽-adrenergic signaling pathway further increases the risk of EADs, where
EADs could occur at shorter cycle length (2000ms versus 4000ms) and lower rapid delayed rectifier K+ current (𝐼Kr) blockage
(77% versus 85%). In summary, this study computationally demonstrated the combined role of CaMKII and 𝛽-adrenergic
signaling pathway on the occurrence of EADs, which could be useful for searching for therapy strategies to treat EADs related
arrhythmogenesis.
1. Introduction
Early afterdepolarizations (EADs) are triggered before the
completion of repolarization [1] and associated with poly-
morphic ventricular tachyarrhythmia for long QT syndrome
patients [2]. Prolongation of action potential duration (APD)
and recovery of L-type Ca2+ current have been reported as
two important factors for the occurrence of EADs [3]. It is
also known that the increase of inward currents (e.g., 𝐼CaL
and late sodium current, 𝐼NaL) or the decrease of outward
currents (e.g., rapid delayed rectifier K+ current, 𝐼Kr and slow
delayed rectifier K+ current, 𝐼Ks) at plateau membrane voltage
could increase the probability of EADs events. Therefore, any
factors that could change the intensity or time sequence of
these currents may lead to the occurrence of EADs [4–8].
Ca2+/calmodulin-dependent protein kinase II (CaMKII)
is a key kinase in tuning cardiac excitation-contraction
coupling. Its substrates include ion channels, transporters,
and accessory proteins [9]. It has been reported that CaMKII
phosphorylates 𝐼CaL, leading to increased amplitude and
APD prolongation and facilitating the occurrence of EADs
[10, 11]. CaMKII can also alter 𝐼NaL, transient outward K
current (𝐼to), SR Ca2+-ATPase (SERCA) [12], and ryanodine
receptor (RyR) channels [10]. It would therefore be useful to
understand and quantify these regulatory roles. However, it is
very difficult for the laboratory experiments to achieve this.
Computer modelling approaches provide alternative ways,
allowing us to distinguish the most effective phosphorylation
target of arrhythmogenesis, which would ultimately provide
useful tool in searching for antiarrhythmia therapy.
It has been known that 𝛽-adrenergic signaling pathway
regulates Ca2+ cycling partly via phosphorylation of 𝐼CaL
and phospholamban (PLB) [13]. 𝐼CaL elevates intracellular
Ca2+ ([Ca]i) and increases spontaneous Ca
2+ release via
the SERCA inhibition by PLB. The broken balance of Ca2+
cycling may contribute to the occurrence of EADs [14–
16]. Volders et al. investigated the ionic mechanisms of 𝛽-
adrenergic on the occurrence of EADs in canine ventricular
myocyte and concluded that cellular Ca2+ overload and spon-
taneous SR Ca2+ release played important roles in EADs [17].
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On the contrary, other studies reported that 𝛽-adrenergic
agonists activate protein kinase A (PKA), which phosphory-
lates 𝐼CaL, RyR, PLB, SERCA, and 𝐼Ks, resulting in delayed
afterdepolarization (DADs) [18]. These numerous targets
and different temporal characteristics of phosphorylation
effects complicate the mechanism analysis of 𝛽-adrenergic
agonists in relation to EADs. Recently, different computa-
tional models have been used to investigate these complex
interactions. Xie et al. developed a biophysically detailed
rabbit model and found that the faster time course of 𝐼CaL
versus 𝐼Ks increased ISO-induced transient EADs [19] and
emphasized the importance of understanding the nonsteady
state of kinetics in meditating 𝛽-adrenergic-induced EADs
and arrhythmia. However, other targets including 𝐼NaL have
not been investigated thoroughly in their model. It is noted
that, although the computational studies of EADmechanisms
have been widely taken, the majority of these published
modelling studies have been developed based on nonhuman
myocyte. Furthermore, to the best of our knowledge, there
is no modelling study considering the combined effect
of CaMKII overexpression and 𝛽-adrenergic agonists on
EADs.
This study aimed to develop a modified computational
model of human ventricular myocyte that integrates CaMKII
and 𝛽-adrenergic signaling networks into a modified ORd’s
dynamic model [20], with which the combined role of
CaMKII and 𝛽-adrenergic signaling pathway on the occur-
rence of EADs would be investigated.
2. Methods
2.1. Integration of CaMKII. Since there is a lack of experi-
mental measurements of human ventricle CaMKII pathway,
O’Hara et al. used the Hund-Decker-Rudy’s dog model to
describe CaMKII kinetics [21, 22]. Our model was developed
from the O’Hara-Rudy dynamic model (ORd model) to
integrate CaMKII pathway [20]. The following equations
describe the CaMKII kinetic of human ventricle:
CaMKbound = CaMK0 ⋅ 1 − CaMKtrap1 + K𝑚CaM/ [Ca2+]ss ,
CaMKactive = CaMKbound + CaMKtrap,
𝑑CaMKtrap
𝑑𝑡 = 𝛼CaMK ⋅ CaMKbound ⋅ (CaMKbound + CaMKtrap) − 𝛽CaMK ⋅ CaMKtrap,
𝛼CaMK = 0.05ms−1, 𝛽CaMK = 0.00068 ms−1, CaMK0 = 0.05, 𝐾𝑚CaM = 0.0015mM.
(1)
The fraction of active CaMKII binding sites at equilib-
rium state (CaMK0) was set to 0.05 at the control state.
CaMK0 of 0.12 was used to simulate CaMKII overexpression
according to the study from Kohlhaas et al. [23].
2.2. Integration of 𝛽-Adrenergic Signaling Networks. The
detailed description of 𝛽-adrenergic signaling networks
could be found from the published study by Soltis and Saucer-
man [24]. PKA has been reported to phosphorylate 𝐼CaL,
PLB, troponin 𝐼, RyR, myosin binding protein-C, protein
phosphates Inhibitor-𝐼 [25], and 𝐼Ks [24]. 𝐼CaL, PLB, and𝐼Ks were the three key factors in this study to model the
inotropic effect of 𝛽-adrenergic related to potential EADs
occurrence. Although the PKA phosphorylation of Na+/K+
ATPase current (𝐼NaK) has been previously described in the
computational models [19, 26], its effect was not included
in this study partially because there is a lack of direct
measurements of 𝐼NaK for the normal human ventricle [20].
The phosphorylation by PKA to the three targets (𝐼CaL, PLB,
and 𝐼Ks) is described as follows:
𝑓avail = 0.017 ⋅ LCC𝑏PKA𝑃f racLCC𝑏𝑝0 + 0.983, (2)
dss = 11.0 + exp (− (𝑉 + Vshif t) /4.230) , (3)
𝐼CaL = (𝐼CaL ⋅ 𝑑 ⋅ (1 − 𝜙𝐼CaL,CaMK)
⋅ (𝑓 ⋅ (1 − n) + 𝑓Ca ⋅ 𝑛 ⋅ 𝑗Ca) + 𝐼CaL,CaMK ⋅ 𝑑
⋅ 𝜙𝐼CaL,CaMK ⋅ (𝑓CaMK ⋅ (1 − 𝑛) + 𝑓Ca,CaMK ⋅ 𝑛 ⋅ 𝑗Ca))
⋅ 𝑓avail,
(4)
Φ𝐼CaL,CaMK = 11 + K𝑚,CaMK/CaMKactive , (5)
𝑡𝑑 = 1.2 ⋅ (0.6
+ 1
exp (−0.05 ⋅ (𝑉 + 6.0)) + exp (0.09 ⋅ (𝑉 + 14.0))) .
(6)
Equation (2) shows the coefficient that represents the
effect of PKA on 𝐼CaL phosphorylation. In (3), the value of
“Vshift” was increased from 3.94 (no ISO application) to 10.0
(for saturated ISO application), which means that the steady
state activation curve of 𝐼CaL was moved left by 6.06mV. The
permeability of ion Ca2+ was increased by 10% with saturated
ISO application. Equation (4) describes the augmentation of𝐼CaL amplitude by multiplying “𝑓avail” with the value without
PKAphosphorylation, and this represents howPKAregulates
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Table 1: Current increment and EADs occurrence when different targets were phosphorylated by CaMKII independently.
Cycle length
(ms)
𝐼Kr blockage
level (%)
CaMKII target
(CaMK0 = 0.12)
Target current variation Deactivationtime (ms) EADs
2000 85
𝐼NaL Decreased by 24%(from 0.25 to 0.19 𝜇A/𝜇F) 1297 versus761ms Alternated
𝐼CaL Increased by 4.2%(from 1.67 to 1.74 𝜇A/𝜇F) No
𝐼CaK Increased by 6.5%(from 0.62 to 0.66𝜇A/𝜇F) No
𝐼CaNa Increased by 8.1%(from 0.37 to 0.40 𝜇A/𝜇F) No
𝐼to Increased by 3.2%(from 0.95 to 0.98 𝜇A/𝜇F) No
𝐼CaL. In (6), the time constant of activation gate (𝑡𝑑) was
extended by 20% with saturated ISO application
frac𝐼Ksavail = 0.49 ⋅ 𝐼KsPKAPfrac𝐼Ksp0 + 0.51, (7)
GKs = frac𝐼Ksavail ⋅ GKs, (8)
𝑋𝑠05 = 11.60 ⋅ f rac𝐼Ksavail, (9)
𝑋𝑆1,∞ = 11 + exp (− (𝑉 + 𝑋𝑠05) /8.932) . (10)
Equation (7) describes the factor of phosphorylation to𝐼Ks by PKA, which was used to alter maximum conductance
of 𝐼Ks (GKs) in (8). Meanwhile, 𝐼Ks state steady activation
curve was adjusted by time dependent gate value through the
factor “frac𝐼Ksavail” in (9) and (10).
2.3. Combination of CaMKII and 𝛽-Adrenergic
Signaling Networks.
𝑓PKAPLB = ( PLB PKA𝑛f racPKAPLB0 ) ⋅
1
4 +
3
4 , (11)
𝑓Jupp = 1.0(1.0 + K𝑚,CaMK ⋅ (𝑓PKAPLB/CaMKactive)) , (12)
Jup = (1.0 − 𝑓Jupp) ⋅ Jupnp + 𝑓Jupp ⋅ Jupp − Jleak. (13)
CaMKactive that is affected by CaMK0 as shown in (1)
would influence 𝐼CaL in (4) via the fraction of 𝐼CaL chan-
nels phosphorylated by CaMKII (Φ𝐼CaL,CaMK ). The fraction of
SERCAs phosphorylated by CaMKII in (12) was affected by
“fPKAPLB” and “CaMKactive”, representing the effects of PKA
and CaMKII on SERCAs, respectively. As shown in (13),
SERCAswere separated into nonphosphorylated populations
and CaMKII phosphorylated populations. Therefore, the
total Ca2+ uptake via SERCAs was adjusted by these two
networks simultaneously.
2.4. Simulation Strategy. In order to determine the poten-
tial targets in CaMKII-induced EADs, CaMKII was solely
overexpressed by assigning the CaMK0of 0.12 to specific
targets (including 𝐼NaL, 𝐼CaL, 𝐼CaK, 𝐼NaCa, and 𝐼to), respectively,
while 𝛽-adrenergic signaling was maintained inactive. Next,
CaMKII overexpression was applied with ISO administra-
tion. 1 𝜇M ISO was applied in this study to simulate its effect
on myocyte action potential and ion currents.
The cycle length of 2000ms was used in this study since it
was closer to normal human beat rhythm than the length of
4000ms used in the experiments fromGuo et al. [27]. In Guo
et al.’s work, EADs appeared with 𝐼Kr blockage of about 85%
[27], which was used for comparison in this study. 500 cycles
were performed when the simulation reached steady state. In
each individual cycle length, the upper bound of solver step
size was set 2ms.
3. Results
3.1. Effect of CaMKII Overexpression on Ion Currents
3.1.1. Late Sodium Current (𝐼NaL). As shown in Table 1 and
Figure 1, with the overexpressed CaMK0 value to 𝐼NaL of 0.12
and the normal CaMK0 value of 0.05 to other targets, the
alternated EADs occur from our simulation with the cycle
length (CL) of 2000ms and 𝐼Kr blockage of 85%.
As shown in Figure 1, INaL amplitudes alternated with
overexpressed CaMK0. In beats with EADs, 𝐼NaL amplitude
was about 24% smaller (0.19𝜇A/𝜇F versus 0.25𝜇A/𝜇F) than
these with normal CaMK0 value to 𝐼NaL and in beats without
EADs, 𝐼NaL amplitude was also reduced by 32% (0.17𝜇A/𝜇F
versus 0.25𝜇A/𝜇F). In Figure 1(d), when EADs occurred,𝐼NaL deactivated, which was about 168% of normal beats
(1297ms versus 773ms) and about 170% of the control
situation in Figure 1(b) (1297ms versus 761ms), indicating
that overexpressed CaMKII phosphorylation level of 𝐼NaL
reduces its amplitude and prolongs 𝐼NaL deactivation process.
Furthermore, the results also indicate that the delayed deacti-
vation of 𝐼NaL, rather than its amplitude variation, contributes
to the formation of EADs.
3.1.2. L-Type Calcium Current (𝐼CaL). Similarly, as shown in
Table 1, with the overexpressed CaMK0 to 𝐼CaL of 0.12 and
4 Computational and Mathematical Methods in Medicine
No EADs Alternated EADs
(b)
(a)
(d)
(c)
V
m
(m
v)
3 41 2 50 7 8 96 10
Time (s)
−100
−50
0
50
V
m
(m
v)
4 1031 5 6 7 8 920
Time (s)
−100
−50
0
50
1 2 3 4 5 60 8 9 107
Time (s)
−0.25
−0.20
−0.15
−0.10
−0.05
0
I N
aL
(𝜇
A
/𝜇
F)
321 4 5 6 8 100 7 9
Time (s)
−0.25
−0.20
−0.15
−0.10
−0.05
0
I N
aL
(𝜇
A
/𝜇
F)
Figure 1: (a) No EAD was produced when CaMKII phosphorylation level was in control (CaMK0 = 0.05). (b) Corresponding 𝐼NaL when no
EADs occurred in (a). (c) Alternated EADs were produced when 𝐼NaL phosphorylation by CaMKII was enhanced with CaMK0 of 0.12 and
other targets’ phosphorylation levels were in control (CaMK0 = 0.05). (d) Corresponding 𝐼NaL when alternated EADs occurred in (c). Under
these conditions, CL was 2000ms and 𝐼Kr was blocked by 85%.
Table 2: Combined effect of CaMKII overexpression and 𝛽-adrenergic agonist on EADs.
Cycle length (ms) ISO application CaMKII target (CaMK0 =
0.12) 𝐼Kr blockage level (%) EADs
2000
None None 85 None
1 𝜇M
None 85 Yes
None 77 No
𝐼NaL 85 Yes
𝐼NaL 77 Yes
𝐼CaL 85 Yes
𝐼CaL 77 No
the normal CaMK0 value of 0.05 to other targets, no EADs
occur at CL of 2000ms and 𝐼Kr blockage of 85%, suggesting
that the probability of EADs might have little relation with
amplitude of 𝐼CaL. With the enhanced CaMK0 value to 𝐼CaL,
the amplitudes of 𝐼CaL only increased by 4.2% (1.74𝜇A/𝜇F
versus 1.67 𝜇A/𝜇F).
3.1.3. K+ Current through the L-Type Ca2+ Channel (𝐼CaK),
Na+ Current through the L-Type Ca2+ Channel (𝐼CaNa), and
Transient Outward K+ Current (𝐼to). As above, CL was set to
2000ms and 𝐼Kr was blocked by 85%. As shown in Table 1,
with enhanced CaMKII phosphorylation level (CaMK0 =
0.12) to different targets, 𝐼CaK increased only by 6.5%
(0.66𝜇A/𝜇F versus 0.62𝜇A/𝜇F), 𝐼CaNa by 8.1% (0.40𝜇A/𝜇F
versus 0.37𝜇A/𝜇F), and 𝐼to by 3.2% (0.98𝜇A/𝜇F versus
0.95𝜇A/𝜇F). No EADs occurred under all these conditions.
3.2. Combined Effect of CaMKII Overexpression
and 𝛽-Adrenergic Agonist
3.2.1. Normal CaMKII and 1 𝜇M ISO. The action potentials
with different 𝐼Kr blockage level are shown in Figure 2. A
fixed CL =2000ms was used and CaMKII phosphorylation
level to all targets was kept control (CaMK0 = 0.05). In
Figure 2(a), with 𝐼Kr blocked by 85%, stable EADs occurred
with the application of ISO, indicating that 𝛽-adrenergic
agonist facilitates EADs. The 𝐼Kr blockage level decreased
gradually from 85%, and, when it was decreased to 77%, as
shown in Figure 2(b), these EADs disappeared, indicating
that 77% was the threshold value for EADs disappearance in
this setting. Therefore, 77% was used in following simulation
to compare with previously published level of 85% [20].These
results are listed from row 2 to row 3 in Table 2.
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Figure 2: (a) EADs were induced when 1 𝜇M ISO was applied and𝐼Kr was blocked by 85%. In (b), EADs disappeared when 𝐼Kr blockage
was reduced to 77%. Cycle length was set 2000ms and CaMKII
phosphorylation level to all targetswas kept control (CaMK0 =0.05).
3.2.2. Enhanced CaMKII to 𝐼NaL and 1 𝜇M ISO. As shown
in Figure 3, with enhanced CaMKII to 𝐼NaL and 1 𝜇M ISO,
when 𝐼Krwas blocked by 85%, EADswere induced.TheEADs
were still observed when 𝐼Kr was blocked by 77%, suggesting
that 𝐼NaL phosphorylation by CaMKII and ISO application
together increased the probability of EADs. These results are
listed from row 4 to row 5 in Table 2.
3.2.3. Enhanced CaMKII to 𝐼CaL and 1 𝜇M ISO. As shown
in Figure 4, with enhanced CaMKII to 𝐼CaL and 1 𝜇M ISO,
when 𝐼Kr was blocked by 85%, EADs were induced, but when𝐼Kr blockage was reduced to 77%, EADs disappeared. These
results are listed from row 6 to row 7 in Table 2.
4. Discussion
This study developed a modified computational model of
human ventricular myocardium cell based on the ORd
human model with the integration of regulation mechanism
by CaMKII and PKA [20], with which their effects on EADs
have been investigated.
EADs often occur during bradycardia under the condi-
tion of reduced repolarization reserve. O’Hara’s group suc-
cessfully elicited EADs with cycle length reduced to 4000ms
and 𝐼Kr blocked by 85% [20]. In our simulation, with the cycle
length halved (2000ms) and 𝐼Kr blocked by 85%, alternated
EADsoccurredwith the sole effect of CaMKII overexpression
to 𝐼NaL, suggesting that ventricular myocardial cell with
CaMKII overexpression is more susceptible to EADs in
normal HR range (CL = 2000ms). Additionally, previous
work has shown that 𝐼CaL plays an important role in the
occurrence of EADs [6].Our simulation showed thatCaMKII
overexpression slightly increased 𝐼CaL amplitude, but this
effect alone did not induce EADs, and CaMKII did not
alter the overlap region of 𝐼CaL steady state activation and
reactivation curves. Zaza et al. reported that [28], when
repolarization is suitably slow, channel reactivationwithin the
overlap regionmay break the current balance and support the
possibility of autoregenerative depolarization. Other inward
currents such as Na+-Ca2+ exchange current (𝐼NaCa) may play
certain roles in triggering EADs if amplitude is augmented
and falls into the overlap region. Our simulation results
suggest that CaMKII enhances these currents but does not
induce EADs via this effect individually. Therefore, when
CaMKII is overexpressed, the susceptibility to EADs is
mainly originated from 𝐼NaL variation.
Our study also demonstrated the behavior of ventricular
myocardial cell with the integration of CaMKII overexpres-
sion and ISO application. With the ISO application, cyclic
AMP (cAMP) is formed through 𝛽-adrenergic mediated
activation of adenylyl cyclase, which activates PKA, a well-
described mediator with targets that promote myocardial
performance. In the case where PKA took effect indepen-
dently, EADs occurred with shorter cycle length (2000ms
versus 4000ms), indicating that the precondition of EADs
is relaxed. Our results were different from that from Xie et
al.’s study, where the APD shortening after ISO application
was observed without EADs in steady state [19]. Xie et al.’s
results could be caused by the simulation of transient 𝐼CaL
recovery and the prevented spontaneous SR Ca2+ release,
limiting the 𝐼NaCa in forward mode.Therefore, when the cells
step into steady state with small inward 𝐼NaCa, the shortening
of APD could be reasonable. In our work, SR Ca2+ release was
enhanced by 𝐼CaL amplification. With the integration with 𝐼Kr
blockage, 𝐼NaCa was more likely to work as inward current,
contributing to the prolongation of APD and occurrence of
EADs. Additionally, the shortening of APDwas also obtained
without 𝐼Kr blockage when 𝛽-adrenergic pathway was acti-
vated. Simulation results showed that when cycle length was
chosen at 500ms, 1000ms, 1500ms, 2000ms, and 4000ms,
the corresponding APD90 shortening was 31.6ms (233.0
versus 201.4ms), 30.5ms (268.6 versus 238.1ms), 22.3ms
(282.6 versus 260.3ms), 17.3ms (289.1 versus 271.8ms), and
18.6ms (305.6 versus 287.0ms). These results were consistent
with the experiment measurements from Volders et al. [29].
In the case that CaMKII overexpression acted on 𝐼NaL alone
with ISO application, EADs occur at CL = 2000ms and 𝐼Kr
blockage by 77%, suggesting that the combination of PKA
and CaMKII overexpression on 𝐼NaL relaxes the precondition
further (𝐼Kr blockage 77% versus 85%) and increases the
probability of EADs. With the CaMKII overexpressed on𝐼CaL alone, PKA induced EADs occurrence with 85% 𝐼Kr
blockage, not 77% 𝐼Kr blockage, suggesting that, with the
ISO application, 𝐼NaL phosphorylation by CaMKII has more
effect on EADs than 𝐼CaL. The steady state of CaMKactive
was simulated with and without ISO application when CL =
2000ms, and their corresponding maximum values were
0.0469 and 0.0421, respectively. This suggests that CaMKII
activation increased with the application of ISO.
Our simulation results have shown that our proposed
model is useful for exploring the interaction of 𝛽-adrenergic
receptor signaling and CaMKII in formation of EADs; some
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Figure 3: EADs occurred when 𝐼Kr was blocked by 85% (a) and 77% (c); corresponding 𝐼NaL when 𝐼Kr was blocked by 85% (b) and 77% (d).
CL was set 2000ms, 1 𝜇M ISO was applied and CaMK0 for 𝐼NaL was set 0.12 independently.
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Figure 4: 1𝜇M ISO was applied and cycle length was 2000ms. CaMK0 for 𝐼CaL was 0.12 but CaMK0 for other targets was 0.05. EADs occurred
when 𝐼Kr was blocked by 85% in (a), but when 𝐼Kr blockage was reduced to 77%, EADs vanished in (c). (b) 𝐼CaL figures when EADs existed.
(d) 𝐼CaL figures when EADs vanished.
potential limitations need to be addressed. Firstly, the role of
CaMKII on RyR function has not been considered. There is
growing evidence about its role in modulating RyR function.
Increasing Ca2+ leak via RyR would limit SR Ca2+ load
and disturb Ca2+ cycling. This should be incorporated into
an improved model in a future study. Secondly, CaMKII
overexpression may downregulate inward rectifier potassium
current (𝐼K1) and increase baseline 𝐼K1 amplitude [30].Wedid
not include any CaMKII effect on 𝐼K1 in our model. Thirdly,
our model only describes the short-term effect of CaMKII
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on different current targets. It has been suggested that short-
term and chronic effects of CaMKII are different [30–33].
Short-term (milliseconds to hours) CaMKII overexpression
may slow 𝐼to inactivation and accelerate recovery, but chronic
overexpression may downregulate 𝐼to,fast and upregulate𝐼to,slow [34]. Therefore, there is a scope to improve our model
by taking chronic effects of CaMKII into consideration in
future. Fourthly, there is a lack of an accurate measurement
about how ISO regulates 𝐼NaK with dynamic calcium change
during the beat cycle, although it has been published by
Gao et al. [35] that ISO regulated INaK increased (when
calcium is 1.4𝜇M) or decreased in pump current (when
calcium is 0.15𝜇M) depending on the intracellular Ca2+
concentrations. In our model the resting calcium concen-
tration was 0.12 𝜇M and the peak calcium concentration
was 1.1 𝜇M. Similar to the simulation work of Heijman et
al. [26], by simply increasing the pump current from 17%
to 33%, no significant change of 𝐼NaK in triggering EADs
(results not shown here) has been observed. However, when
the continuous experimental data from human ventricular
cells is available, the regulation of ISO on 𝐼NaK could be
incorporated into the model to reconfirm this nonsignificant
effect. Fifthly, it has been reported that local regulation of
cAMP and substrate phosphorylation play important roles
in 𝛽-adrenergic receptor signaling [26, 36–38], so it could
be useful to incorporate local control mechanism in a future
study. Lastly, there are four CaMKII isoforms (𝛼, 𝛽, 𝛾, 𝛿) with
different distributions, kinetics, and roles in physiological
and pathological adjustments. Until now, these differences
have not been fully understood. Developing a model with
detailed CaMKII isoforms information could be useful when
experiment data are available.
In conclusion, our simulation results computationally
demonstrated a better understanding of the combinational
effect of CaMKII and ISO stimulus on the occurrence of
EADs in human ventricular myocyte, which may provide
useful tool to research therapeutic methods for the treatment
of arrhythmia.
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